We are developing a nanotechnology approach to enhance the solubility, bioavailability, and effectiveness of API crystals by improving their water solubility without altering the crystal structure. The technology aims to reformulate various insoluble APIs falling under BCS Class II and IV with bioabsorbable, functionalized nanoparticles to enhance solubility and ultimately efficacy. These fast-dissolving APIs will be applicable in oral, transdermal, inhalation, and injectable formulations, lowering the required dosage and thereby reducing side effects and toxicity.